Actinium Pharmaceuticals, Inc.– Leading the next revolution in targeted radiotherapy.

Actinium Pharmaceuticals – Leading the next revolution in targeted radiotherapy. Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies, which combine the targeting ability of molecules like antibodies with the cell-killing ability of radiation. Actinium’s lead asset, Iomab-B, is being studied in the pivotal Phase 3 SIERRA trial where it is being evaluated as a targeted conditioning agent prior to a potentially curative bone marrow transplant in patients with active, relapsed, or refractory acute myeloid leukemia. With a growing IP portfolio with over 140 patents & significant know-how, Actinium Pharmaceuticals hopes to leverage the proven modality of radiation but delivering it with precision inside the body to fully realize its potential and improve patient outcomes for both hematological malignancies as well as solid tumors. Actinium Pharmaceuticals is also committed to staying at the forefront of innovation, collaborating with leading global biopharmaceuticals companies like Astellas, Inc., using its targeted radiotherapies as part of the regimen for cell & gene therapies.